|
May 14
|
Legend Biotech Corp (LEGN) Q1 2024 Earnings Call Transcript Highlights: Soaring CARVYKTI Sales ...
|
|
May 14
|
Q1 2024 Legend Biotech Corp Earnings Call
|
|
May 13
|
Legend Biotech Reports First Quarter 2024 Results and Recent Highlights
|
|
May 9
|
Should You Buy Legend Biotech (LEGN) Ahead of Earnings?
|
|
Apr 22
|
CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma
|
|
Apr 11
|
Legend Biotech to Host Investor Conference Call on First Quarter 2024 Results
|
|
Apr 8
|
FDA Expands J&J's (JNJ) Carvykti Label in Multiple Myeloma
|
|
Apr 8
|
Why Legend Biotech (LEGN) Stock Might be a Great Pick
|
|
Apr 6
|
Legend Biotech’s CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma
|
|
Apr 3
|
Should You Continue to Hold Legend Biotech Corporation (LEGN)?
|
|
Mar 29
|
Management’s Conservative Guidance Led Legend Biotech Corporation (LEGN) to Decline in Q4
|
|
Mar 19
|
Legend Biotech Announces Publication of Inaugural Environmental, Social and Governance (ESG) Report
|
|
Mar 17
|
30 Biggest Biotechnology Companies in the World
|
|
Mar 15
|
CARVYKTI® (ciltacabtagene autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma
|
|
Mar 12
|
Legend Biotech Corporation (NASDAQ:LEGN) Q4 2023 Earnings Call Transcript
|
|
Mar 11
|
The Zacks Analyst Blog Highlights Legend Biotech, Exact Sciences, Exelixis, Ascendis Pharma and MorphoSys
|
|
Mar 11
|
Legend Biotech Reports Fourth Quarter and Full Year 2023 Results and Recent Highlights
|
|
Mar 8
|
5 Biotechnology Stocks to Buy for a Stable Portfolio in 2024
|
|
Jan 3
|
Legend Biotech Announces Closing of License Transaction for Certain CAR-T Therapies Targeting DLL3
|
|
Jan 2
|
Why healthcare, biotech may be top plays for 2024: BTIG
|